It has been about a month since the last earnings report for Albemarle (ALB - Free Report) . Shares have lost about 34.3% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Albemarle due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important catalysts.
Albemarle’s Q4 Earnings & Sales Miss, View Disappoints
Albemarle recorded a profit of $90.4 million or 85 cents per share in the fourth quarter of 2019, down around 30% from $129.6 million or $1.21 per share it earned year ago.
Adjusted earnings for the reported quarter were $1.73 per share, up roughly 13% year over year. It lagged the Zacks Consensus Estimate of $1.75.
Revenues rose around 8% year over year to $992.6 million in the quarter. It, however, missed the Zacks Consensus Estimate of $1,001 million. Revenues were aided by higher volumes in the Lithium unit and favorable pricing in Bromine Specialties and Catalysts segments.
Sales from the Lithium unit climbed around 20% year over year to $411.1 million in the reported quarter, aided by favorable sales volumes. Pricing was flat in the quarter. Adjusted EBITDA was down roughly 3% year over year to $140.1 million.
The Bromine Specialties segment recorded sales of $243.5 million, up around 2% year over year, supported by favorable pricing and product mix. Adjusted EBITDA was $79.7 million, up around 14% year over year.
The Catalysts unit recorded revenues of $282.5 million in the reported quarter, down roughly 7% year over year. Adjusted EBITDA was $76.7 million, down roughly 3% year over year. The company saw lower sales in Clean Fuel Technology as well as Fluid Catalytic Cracking (“FCC”) due to delays in the start-up of new FCC units.
Earnings for 2019 were $5.02 per share, down from $6.34 per share a year ago.
Revenues were $3.6 billion for the full year, up around 6% year over year.
Albemarle ended 2019 with cash and cash equivalents of roughly $613.1 million, up roughly 10% year over year. Long-term debt doubled year over year to around $2,862.9 million.
Cash flow from operations was $719.4 million for 2019, up around 32% year over year. Capital expenditures were $851.8 million for the year, up 22% year over year.
Albemarle envisions its results in 2020 to be lower on a year-over-year basis factoring in lower expected results from the Lithium segment and flat-to-modestly lower results from the Bromine Specialties unit, partly offset by flat-to-slightly higher results from the Catalysts division.
The company expects net sales for 2020 to be between $3.48 billion and $3.53 billion, representing 2-3% year over year decline. Moreover, Albemarle sees adjusted earnings for 2020 in the band of $4.80-$5.10 per share, a year-over-year drop of 16-21%.
Adjusted EBITDA for the year has been forecast in the range of $880-$930 million, representing 10-15% year over year decline.
The company also expects its cost-reduction program to deliver run-rate savings of more than $100 million by the end of 2021.
How Have Estimates Been Moving Since Then?
It turns out, estimates review have trended downward during the past month. The consensus estimate has shifted -17.33% due to these changes.
Currently, Albemarle has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Following the exact same course, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Estimates have been broadly trending downward for the stock, and the magnitude of this revision indicates a downward shift. Notably, Albemarle has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.